AAMC CHARGE
Informational Webinar:

BMSF Diversity in Clinical Trials Career Development Program

January 19, 2021
AAMC Health Equity Research and Policy Team
An equitable and just society in which academic health centers:

• Prioritize health equity scholarship and research across the full spectrum of scientific inquiry.
• Partner with communities, families, and patients to develop solutions to health injustice.
• Advocate for structural changes that address the root causes of health inequities.

AAMC CHARGE cultivates the health equity community by advancing collaborative research, policy, and programmatic solutions to health and health care inequities.

Our Vision
An equitable and just society in which academic health centers:

• Prioritize health equity scholarship and research across the full spectrum of scientific inquiry.
• Partner with communities, families, and patients to develop solutions to health injustice.
• Advocate for structural changes that address the root causes of health inequities.

How can I get involved?
To learn more about and/or join AAMC CHARGE, visit www.aamc.org/charge. For more information about getting involved, please email healthequityresearch@aamc.org.
Catharine Grimes, MBA
Director
Bristol Myers Squibb Foundation

Joy L. Jones, PhD
Chief Program Officer
National Medical Fellowships, Inc.
Diversity in Clinical Trials Career Development Program (DCTCDP)
Overview

Winter 2020/2021
Welcome

- Welcome and Introductions
  - Catharine Grimes, Director, Bristol Myers Squibb Foundation (BMSF)
  - Joy L. Jones, Chief Program Officer, National Medical Fellowships (NMF)

- BMSF DCTCDP National Advisory Committee (NAC)
  - Robert A. Winn, MD, NAC Chair

- Program Overview
  - Catharine Grimes, MBA
  - Joy L. Jones, PhD
Promotes health equity and seeks to improve the health outcomes of populations disproportionately affected by serious diseases by strengthening healthcare worker capacity, integrating medical care and community supportive services, and mobilizing communities in the fight against disease.
NMF’s vision is to empower and support aspiring physicians and health professionals underrepresented in medicine to contribute to the health of our nation.

We envision a diverse healthcare workforce which will have the leadership, commitment and cultural competency to achieve health equity.

NMF’s mission is to provide scholarships and support for underrepresented minority students in medicine and the health professions.
Welcome from NAC Chair

https://diversityinclinicaltrials.org/our-vision

Robert A. Winn, MD
Cancer Center Director of the Massey Cancer Center at Virginia Commonwealth University
Chair, BMSF DCTCDP NAC
Bristol Myers Squibb Foundation
Diversity in Clinical Trials
Career Development Program

Catharine Grimes, MBA
Director, Bristol Myers Squibb Foundation

Joy L. Jones, PhD
Chief Program Officer, National Medical Fellowships
# The need for diversity in clinical trials

<table>
<thead>
<tr>
<th>Definition of Diversity in Clinical Trials</th>
<th>Benefits of Diversity in Clinical Trials</th>
<th>Current State of Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Engage a patient population that mirrors the epidemiology of the disease studied</td>
<td>• Better Science. Safety and efficacy of new medicines should be assessed in the patients with the condition</td>
<td>• Black Americans represent 13% of the US population but reflect only about 4% of participants in clinical trials</td>
</tr>
<tr>
<td>• Assure the ecosystem around the trials reflects diverse populations being served. Includes research sites, principal investigators, and extended care teams</td>
<td>• Personalized Medicine. Understanding the range of different responses to treatments based on genetic variations</td>
<td>• Hispanics represent 16% of the US population but only about 3% of clinical trial participants</td>
</tr>
<tr>
<td>• Design in inclusivity from start</td>
<td>• Data. Better inform treatment decisions by making new options available to patients</td>
<td>• In general, 80% of patients taking part in clinical trials are white*</td>
</tr>
<tr>
<td></td>
<td>• Address disparity and inequity</td>
<td></td>
</tr>
</tbody>
</table>

---

(1) “CDC Heart Disease Facts” [https://www.cdc.gov/heartdisease/facts.htm](https://www.cdc.gov/heartdisease/facts.htm)
(3) The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity [http://cebp.aacrjournals.org/content/25/10/1371](http://cebp.aacrjournals.org/content/25/10/1371)
Diversity in Clinical Trials Career Development Program

Bristol Myers Squibb Foundation $100 MM Commitment over 5 years

Comprehensive and integrated approach to increase diversity in clinical trials through workforce development AND clinical trial site development in underserved communities where underrepresented patients receive care

Do better in urban areas:
Support established clinical trials sites/centers of excellence to engage with nearby community and safety net healthcare delivery institutions to enhance their clinical trial capacity and to collaborate on research

Expand in rural/trial “desert” areas with high disease burden:
Support transition of research naïve sites to fully functional clinical trial sites serving underrepresented populations
Diversity in Clinical Trials Career Development Program

Goals
• To transform the clinical research landscape by building and strengthening partnerships between clinical investigators and the communities where their patients reside.
• To facilitate an approach to clinical and translational research that is community-informed, designed and conducted.

Approach
• Provide training and resources to build a network of URM clinical investigators with community engagement and research skills.
• Expand the number of community-based sites with the capacity to conduct clinical and translational research.

Outcome
Increased participation of diverse patients in clinical and translational research.

Impact
Improved public health through an increase in the development of new drugs, vaccines and therapeutic products that are effective in all populations.
### Key Program Elements

| Commitment | Train and develop 250 new clinical investigators dedicated to increasing diversity in clinical trials (~50/year)  
|            | Provide immersive community-based experiences in clinical trial research to 250 underrepresented minority medical students (Note: The Pipeline program will launch in the summer of 2022. Applications will open in Oct/Nov 2021). |
| Award      | $120K/year for 2 years; require at least 40% of Scholar’s time (Note: Awards will be given to organizations, not to individuals.)  
|            | **Guidance for the award:** It is expected that the award will cover a percentage of the Scholar’s salary to garner 40% of his/her time. Additionally, funds can be used toward a portion of a research assistant/coordinator salary. If funds are used for indirect costs, the amount cannot exceed $10,000 or 10% of the recommended salary offset. |
| Mentoring  | Scholar will be mentored by a Principal Investigator at an established clinical trial site, and will substantively participate in the PI’s active clinical trial (it is not expected that the scholar will have his/her own clinical trial). |
| Training   | Scholars will be trained in investigator-initiated and industry-sponsored clinical trials, as well as in community outreach and engagement processes and methods. |
| Pipeline program | Scholar will serve as a mentor to an URM medical student during the 2nd program year. 250 URM medical students (50/year) will participate in a 6- to 8-week summer immersion program learning the basics of clinical trials and working in underserved community clinics and federally qualified health centers to provide outreach, education and engagement on clinical trials. The Pipeline program will launch in the summer of 2022. Applications will open in Oct/Nov 2021. |
| Clinical research focus areas | Cancer (Hematology and Oncology), Cardiovascular Disease and Immunologic Disorders |
## Candidate Eligibility Criteria

| Candidate Profile                                                                 | Eligible candidates will reflect the National Science Foundation (NSF) definition of underrepresented populations in the US Biomedical, Clinical, Behavioral and Social Sciences Research Enterprise:  
|                                                                                   | • African Americans or Blacks  
|                                                                                   | • Hispanics or Latinos  
|                                                                                   | • American Indians or Alaska Natives  
|                                                                                   | • Native Hawaiians  
|                                                                                   | • Other Pacific Islanders  
|                                                                                   | OR have a demonstrated commitment to increasing diverse patient participation in clinical trials |
| Citizenship or Immigration Status                                                 | Eligible candidates will be US Citizens or Lawful Permanent Residents (LPRs) as defined by the [US Department of Homeland Security](https://www.dhs.gov). |
| Professional Degree                                                              | Eligible candidates will hold the degree of MD, MD/PhD, DO or DO/PhD |
| Career Phase                                                                     | **Early Stage Investigator (ESI):** As defined by NIH, a new investigator who has completed his or her terminal research degree or medical residency—whichever date is later—within the past 10 years and has not yet competed successfully for a substantial, competing NIH research grant.
BMSF DCTCDP: Timeline

Sept.-Oct. 2020
Draft the Program Model and Form the Advisory Committee

Nov. 17, 2020
National Announcement

July 2, 2021
Application Closes

Sept. 1, 2021
Selection Announcement

Inaugural National Advisory Committee (NAC) Meeting
Nov. 4, 2020

Application Opens
LOI, then Full Proposal
Jan. 2021

First Cohort Begins
Sept. 15, 2021

Selection Process
July 2-Aug 31, 2021

Sept. 1, 2021
National Announcement

 Application Closes

July 2, 2021

Selection Process

July 2-Aug 31, 2021

First Cohort Begins

Sept. 15, 2021

National Announcement

Application Closes

July 2, 2021

Selection Process

July 2-Aug 31, 2021

First Cohort Begins

Sept. 15, 2021
How to Apply to the DCTCDP
Application Process with Key Target Dates

The BMSF DCTCDP application will be a 2-step process, which includes:

1) Submission of a Letter of Intent (LOI), and
2) Upon review, selected candidates will be invited to submit a full Application.

<table>
<thead>
<tr>
<th>Application Process Opens: Letter of Intent &amp; Invited Full Application</th>
<th>Jan 4, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Closes:</td>
<td>July 2, 2021</td>
</tr>
<tr>
<td>Selection Process:</td>
<td>July 2-Aug 31, 2021</td>
</tr>
<tr>
<td>Selection Announcement:</td>
<td>Sep 1, 2021</td>
</tr>
<tr>
<td>First Cohort Begins:</td>
<td>Sep 15, 2021</td>
</tr>
</tbody>
</table>

Note: Dates are subject to change.
Letter of Intent - Step 1

- Degree and dates received
- List clinical specialty and sub-specialty
- Self-identify racial or ethnic minority group OR indicate Other and describe your demonstrated commitment to diversity in clinical trials
- Position / Job title and start date
- Name and location of institution / organization
- Does your institution support your application?
- Do you have a potential mentor identified at your institution with whom you can participate on an ongoing clinical trial?
- List all current sources of funding
- List all significant publications within the last 2-3 years
- Submit current CV (within 6 months)
- Indicate your experience with the design of clinical trials studies or participation in clinical trial research
- Provide a brief description of the research you aspire to participate in during the 2-yr BMSF DCTCDP (limit 300 words)
- Provide a brief description of how you see this program advancing your career and your ability to contribute to increasing diversity in clinical trials (limit 300 words)
National Advisory Committee (NAC)

CHAIR
Robert Winn, MD
Director, Massey Cancer Center
Senior Associate Dean for Cancer Innovation
Professor, Division of Pulmonary Disease and Critical Care Medicine
Virginia Commonwealth University

MEMBERS
Leon Bernal-Mizrachi, MD
Associate Professor, Department of Hematology & Medical Oncology
Service Chief, Hematology and Medical Oncology
Associate Director, Hematology and Medical Oncology Fellowships Program
Emory University School of Medicine & Grady Health Systems

Nancy Daly, RN, MS, MPM
Executive Vice President & Chief Executive Officer
Conquer Cancer and the ASCO Foundation

Gail Kerr, MD, FRCP
Professor of Medicine & Chief of Rheumatology at Howard University Hospital
Howard University

José López, MD
Chief Scientific Officer & Full Member
Blood Works Northwest Research Institute
Professor of Medicine, Division of Hematology
University of Washington School of Medicine

Ruben Mesa, MD, FACP
Presidential Chair, Mays Family Foundation
Distinguished University Professor of Medicine
UT Health San Antonio MD Anderson

Lucio Miele, MD, PhD
Professor and Department Head, LSU School of Medicine, Department of Genetics
Director for Inter-Institutional Programs, LSU Stanley Scott Cancer Center & Louisiana Cancer Research Consortium
Cancer Crusaders Endowed Professor in Cancer Research
Louisiana State University Health Sciences Center

Edith Mitchell, MD, MACP, FCPP
Clinical Professor of Medicine and Medical Oncology
Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson Health

Kathryn Owen
Vice President
Head of Global Development Operations
Bristol Myers Squibb

Eliseo J. Pérez-Stable, MD
Director, National Institute on Minority Health and Health Disparities
National Institutes of Health

Lori Pierce, MD
Professor, Department of Radiation Oncology
Vice Provost for Academic and Faculty Affairs
Michigan Medicine, University of Michigan

Amelie G. Ramirez, DrPH, MPH
Director & Professor, Institute for Health Promotion Research, Graduate School of Biomedical Sciences
UT Health San Antonio

Brian Rivers, PhD, MPH
Director, Cancer Health Equity Institute, National Center for Primary Care
Morehouse School of Medicine

Hannah Valantine, MD
Professor, Cardiovascular Medicine
Stanford University Medical Center
Prior: Chief Officer for Scientific Workforce Diversity, National Institutes of Health

Annabelle Voigman, MD, FACC, FAHA
McMullan-Eybel Chair of Excellence in Clinical Cardiology
Professor of Medicine, Rush College of Medicine
Medical Director, Rush Heart Center for Women
Rush University

Karen Winkfield, MD, PhD
Executive Director
Meharry-Vanderbilt Alliance
Vanderbilt University Medical Center

Winston Wong, MD, MS, FAAFP
Scholar-in-Residence, UCLA Kaiser Permanente Center for Health Equity
UCLA Fielding School of Public Health
QUESTIONS
Thank you for your interest in the BMS Foundation DCTCDP!


Direct inquiries to: DCTCDPinfo@nmfonline.org

Program website: [www.diversityinclinicaltrials.org](http://www.diversityinclinicaltrials.org)
AAMC Health Equity Research and Policy

Sign up for updates about the latest health equity funding announcements, tools, and professional development opportunities at:

aamc.org/healthequity